Dr. Mark T. Reding, MD

Dr. Reding practices at M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview.

Dr. Reding's NPI, 1336223866, was assigned on October 24, 2006. Dr. Reding graduated from University Of Minnesota Medical School in 1992. Dr. Reding holds Minnesota license 37501.

Dr. Reding's primary practice is M Health Fairview University of Minnesota Medical Center, at 2450 Riverside Avenue, Minneapolis, MN 55454 in Hennepin County. The practice phone is (612) 624-1765.

Dr. Reding's primary practice is M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview. Dr. Reding is also affiliated with M Health Fairview Southdale Hospital. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Reding to 1 more hospital, 6 medical groups, 4 group practices and clinics and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reding practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Reding's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Reding is licensed in Minnesota.

Dmand AI lists chronic anemia, chronic embolism thrombosis, chronic leukemia and purpura and thrombocytopenia among the conditions Dr. Reding treats.

CMS data shows 112 Medicare services from Dr. Reding across 4 procedure codes in 2024, for 114 Medicare patients. Medicare paid $9,323 for them.

CMS counts 114 Medicare patients who saw Dr. Reding in 2024. The largest group is under 65, with 44 patients. 62% of them have high blood pressure, and 53% have arthritis. 33% are also on Medicaid. Their average risk score is 3.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reding's median patient age at 59, with 61% women.

In 2024, Dr. Reding wrote 516 Medicare Part D claims for 83 patients. 54% of them were for generic drugs. CMS names the drug for 444 of them, across 16 drugs with 11 or more claims each, at $784,941 in total drug cost. In 2023, CMS named 386 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Reding for performance year 2024, reported as part of a group. Dr. Reding accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Reding as offering telehealth.

Dmand AI links 60 papers to Dr. Reding, published from 2012 to 2024. 2021 was the busiest year, with 6. The most frequent topics are Hemophilia A, Factor VIII and Hemorrhage. Dr. Reding has published most often in Haemophilia. Dr. Reding's most frequent co-authors are Doris Voy Kan Quon, MD, Miguel A. Escobar, MD and Steven W. Pipe, MD.

Dmand AI links Dr. Reding to 1 clinical trial. Conditions studied include Venous Thrombosis and Thrombosis.

CMS Open Payments shows 661 general payments to Dr. Reding from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 48% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $130,905.

Dr. Reding graduated from University Of Minnesota Medical School in 1992.

Dr. Reding is in network with 16 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.